Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...

German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks Therapeutics for around ...

Germany’s Merck agreed to acquire U.S. biopharmaceutical company SpringWorks Therapeutics for around $3.9 billion, in a bid ...

Merck & Company, Inc. (MRK) to acquire SpringWorks Therapeutics, Inc. (SWTX) for $47/share in cash, creating synergies for ...

Planned acquisition will strengthen the US presence of Merck Healthcare and expand reach of SpringWorks’ therapeutic ...

German pharmaceutical company Merck announced Monday that it has reached an agreement to acquire U.S.-based SpringWorks Therapeutics for approximately ...

After developing treatments for rare tumors, SpringWorks Therapeutics is taking a buyout offer from Germany-based Merck KGaA.

Merck KGaA plans to acquire SpringWorks Therapeutics, a Connecticut-based specialist in biopharmaceuticals for severe rare diseases and cancer ...

Current health news highlights include a dispute over EU drug pricing proposals, a U.S.-Mexico accord on screwworm management ...

U.S. stock futures are little changed as investors ready for a busy earrings calendar, including upcoming reports from Apple, ...

Two months after confirming “advanced talks” for a potential merger, Stamford-based SpringWorks Therapeutics Inc. on Monday ...